LPLV 2 Months Ahead of Schedule
ARG CEO Paul Bishop just received the following feedback from a Global Pharmaceutical Sponsor: “LPLV occurred on Friday. Congrats to […]
Shay Brill Earns Master’s Degree in Clinical Research Administration from GWU
Why did you choose to pursue this MS? Shay: “My goal was to verify my industry knowledge through formal studies. […]
Pivotal Phase III trial undergoes audits by the FDA and sponsor
Challenge: A pivotal Phase III clinical trial of C1 inhibitor for the prophylactic treatment of hereditary angioedema managed by ARG […]
ARG Strategic Advisory Board Meeting 5/24
The ARG SAB (Strategic Advisory Board) regularly convenes to discuss emerging trends and issues in rare diseases, adding to the […]
Does Your CRO Understand the Ultimate Trial Goal?
ARG’s primary goal is to improve and prolong the lives of the people affected by rare diseases through the clinical trials we manage. We realize our patient-centric approach by carefully cultivating relationships, fostering meaningful communication, and anticipating and addressing all of the challenges in our studies.